Quarterly Results • Search Archive
Gujarat Themis Biosyn Limited
Results, Financials & Updates
Follow Gujarat Themis Biosyn Limited results and financial updates in one company page: latest revenue or income, profit, margins, quarter comparisons, what changed and detailed Nivata Results deep dives.
1 published deep dive
1 quarter 1 sector
Company Overview
Gujarat Themis Biosyn Limited: latest results and financials
About the business in Nivata's latest coverage
Gujarat Themis Biosyn Limited (GTBL) operates as a specialized manufacturer of fermentation-based pharmaceutical intermediates and active pharmaceutical ingredients (APIs). Established in 1981 as a joint sector company with GIIC Ltd. and Chemosyn (P) Ltd., GTBL pioneered the commercial production of the anti-tuberculosis drug Rifampicin in India using fermentation processes. The company's core product portfolio centers around rifamycin-based derivatives, including Rifamycin S (an intermediate for Rifampicin used in treating tuberculosis, mycobacterium avium complex, leprosy, and Legionnaires' disease) and Rifamycin O (an intermediate for Rifaximin used in traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy).
Quarter history
Gujarat Themis Biosyn Limited Results & Financials
Latest Nivata coverage: Q1 FY27 · revenue ₹43.79 Cr · PAT ₹11.07 Cr.
Nivata currently has one covered quarter for this company. This page remains the stable company-results hub and expands automatically as additional quarters are published.